Anest. intenziv. Med. 2013;24(4):230-236

Anaesthesia for irreversible electroporation (IRE) prostatectomy: Reversal of neuromuscular blockade with sugammadex vs neostigmin. Retrospective studyAnaesthesiology - Original Paper

Herold Ivan1,*, Sittová Naděžda1, Čurdová Marcela1, Kolombo Ivan2, Pabišta Richard3, Adamus Milan4
1 Anesteziologicko-resuscitační oddělení, Oblastní nemocnice Mladá Boleslav, a. s.
2 Centrum robotické chirurgie a urologie, Nemocnice Na Homolce, Praha
3 Urologické oddělení, Oblastní nemocnice Mladá Boleslav, a. s.
4 Klinika anesteziologie, resuscitace a intenzivní medicíny, FN a LF UP v Olomouci

Objective:
Assessment of factors influencing the reversal of neuromuscular blockade with sugammadex (S) and neostigmin (N) in IRE prostatectomy requiring deep neuromuscular block until the end of surgery.


Type:
Retrospective study, analysis of anaesthesia charts.


Setting:
Department of Urology, Department of Anaesthe-siology and Intensive Therapy.

Materials and methods:
During a 5-month period (November 2011-March 2012) IRE prostatectomy were performed in 35 men in balanced general anaesthesia with rocuronium. At the end of surgery, S 200 mg (BRIDION) or N (NEOSTIGMIN) were administered for the reversal of deep block (TOF-count 0, PTC ≥ 5) or moderate block (TOF-count ≥ 1) respectively. We analysed the relation of the reversal to the rocuronium admini-stration: the intubation dose, total dose (absolute, per kg of body weight, number of supplementing boluses), duration of anaesthesia and ASA using non-parametric Mann Whitney and Fischer exact tests. Results are presented as mean values.

Results:
Sugammadex 200 mg (2.21 mg/kg) was administered in 22 (63%) patients with deep block (BRIDION group), neostigmin (0.027 mg/kg) in 13 (37%) patients with moderate block (NEOSTIGMIN group). Comparing to NEOSTIGMIN, higher doses of rocuronium - absolute dose (82.5 vs 65 mg, p = 0.001) and dose/kg bw (0.85 vs 0.69 mg/kg, p = 0.018) were given, the number of rocuronium boluses was higher (p = 0.013) and the anaesthesia was longer (100 vs 90 min, p = 0.044) in the BRIDION group. A dose of S 200 mg was sufficient in 20 patients (91 %) for block reversal. In 2 patients with a lower sugammadex dose (< 1.6 mg/kg), a supplement dose of 100 mg was required for complete block recovery after 3.5 min.

Conclusion:
In IRE prostatectomy, rocuronium-sugammadex combination appears to be a cost-effective strategy. A standard dose of 200 mg sugammadex at the end of surgery might be insufficient in obese patients (in doses < 1.6 mg/kg).

Keywords: neuromuscular blockade; akcelerometry; reversal; neostigmin; sugammadex; prostatectomy; irreversible electroporation

Received: April 20, 2013; Accepted: May 5, 2013; Published: August 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Herold I, Sittová N, Čurdová M, Kolombo I, Pabišta R, Adamus M. Anaesthesia for irreversible electroporation (IRE) prostatectomy: Reversal of neuromuscular blockade with sugammadex vs neostigmin. Retrospective study. Anest. intenziv. Med. 2013;24(4):230-236.
Download citation

References

  1. Haimowitch, L. Interest grows with least - invasive approaches taken by interventional oncology practitionares. Biomedical Bussiness and Technology, 2008, 31, p. 5-8.
  2. Biki, B., Mascha, E., Moriarty, D., Fitzpatrick, J., Sessler, D., Buggy D. Anesthetic technique for radical prostatectomy surgery affects cancer reccurence. Anesthesiology, 2008, 109, p. 180-187. Go to original source... Go to PubMed...
  3. Rubinski, B. Irreversible electroporation in Medicine. Technology in Cancer Research and Treatment, 2007, 6, p. 255-259. Go to original source... Go to PubMed...
  4. Nikolski, V., Efimov, P. Electroporation of the heart. Europace, 2005, 7, p. S146-S157. Go to original source... Go to PubMed...
  5. Onik, G., Mikus, P., Rubinsky, B. Irreversible electroporation: implications for prostate ablation. Technology in Cancer Research and Treatment, 2007, 6, p. 295-300. Go to original source... Go to PubMed...
  6. Esser, A., Smith, K., Gowrishankar, T., Weaver, J. Towards solid tumor treatment by irreversible electoporation: Intrinsic redstributionof fileds and currents in tissue. Technology in Cancer Research and Treatment, 2007, 6, p. 261-273. Go to original source... Go to PubMed...
  7. Rubinsky, J., Onik, G., Mikus, P. et al. Optimal parameters for the destruction of prostate cancer using irreversible electroporation. J. Urol., 2008, 180, p. 2668-2674. Go to original source... Go to PubMed...
  8. Ball, C., Thomson, K. R., Kavnoudias, H. Irreversible electroporation: a new challenge in "out of operating theater" anesthesia. Anesth. Analg., 2010, 110, p. 1305-1309. Go to original source... Go to PubMed...
  9. Málek, J., Šturma, J., Janík, V., Kurzová, A. Anesteziologická problematika CT navigované ireverzibilní elektroporatizace(přístroj NanoKnife&trade). Anest. Intenziv. Med., 2013, 2, p. 83-89.
  10. Kolombo, I. Nová technologie miniinvazivní terapie maligních tumorů - NanoKnife® [cit. 2013-04-24]. Dostupný na:http://www.sab-medical.com/nano-knife.php.
  11. Brausi, M., Gibert, G., Botiicelli, L., Di Gregio, C. Irreversible electroporation, a novel technique for focal ablation of prostate cancer (PCA): Results of a interim pilot safety study in low risk patients with PCA. Eur. Urolog. Suppl., 2011, 10, p. 300. Go to original source...
  12. Eleveld, D. J., Kuizenga, K., Proost, J. K., Wierda, J. M. A temporary decrease in twitch response during reversal or rocuronium-induced muscle relaxation with small dose of sugammadex. Anesth. Analg., 2007, 104, 3, p. 582-584. Go to original source... Go to PubMed...
  13. Fuchs-Buder, T. Less is not always more: sugammadex and the risk of underdosing. Eur. J. Anaesthesiol., 2010, 27, 10, p. 849-854. Go to original source... Go to PubMed...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.